We examine the structural bias for established estimators of vaccine e ects on susceptibility and for newer estimates of vaccine e ects on infectiousness. We then propose and analyse new bias corrections for vaccine e ect estimators of both susceptibility and infectiousness, as well as their combined e ect on infection transmission. Each estimator is evaluated empirically with computer simulations. Of the estimators examined in this paper, those with the least bias and root mean squared error are computed by adding one to the positive count in the placebo population. We also identify a source of bias for a standard Bayesian estimator of risk ratios.
INTRODUCTION
Vaccination programmes have proven to be an e ective intervention for many infectious diseases. One important vaccine e ect is to prevent the reproduction of a infectious agent so that a vaccinated individual is no longer susceptible to infection, regardless of how many times exposure occurs. This is a model II vaccine e ect on susceptibility, in the nomenclature of Smith et al. [1] , that imparts complete immunity to infection for a fraction of vaccine recipients. However, there are several other vaccine e ects that may also reduce the transmission of infectious agents in a population as well. The induced immune response may keep agents from reaching a niche where they can reproduce in a way that reduces the probability infection per exposure [2; 3] , known as a model I [1] vaccine e ect on susceptibility. Alternatively, the vaccine induced immune response can slow agent reproduction, lower the level of agent generated, and thus decrease the contagiousness of the host. This reduces the probability that a vaccinated, infected individual may transmit infection to others, an infectiousness e ect that reduces the rate of secondary infections. The oral polio vaccine, H. in uenzae type b vaccine, and the malaria transmission-blocking vaccine demonstrate the importance of measuring these di erent vaccine e ects [4; 5] . Additionally, HIV vaccines may need to rely on infectiousness e ects to slow the HIV epidemic [5; 6] , as HIV-1 viral load is an important risk factor in heterosexual transmission [7] .
There is therefore great interest in obtaining accurate estimates of vaccine e ects for susceptibility (VE S ) and infectiousness (VE I ), as well as their combined e ect (VE R ) on the basic reproduction number [8] of the infectious agent. Several trial designs have been proposed to estimate those e ects using maximum likelihood techniques [5; 6; 9] .
Vaccine e ect estimators, however, may be biased for a number of reasons, including sample selection bias, observer bias, confounding between vaccination and exposure, population heterogeneity, dependencies between exposure risks and infection experience in trial subjects, lack of speciÿcity in the case deÿnition for disease, and the use of an incorrect statistical model [10] [11] [12] [13] [14] [15] [16] .
Although the standard vaccine e ect estimators are consistent, they are biased because they are non-linear functions of other estimators [17] . This leads to a systematic underestimation of vaccine e ects, in expectation, even if other sources of bias are completely eliminated. While the bias may be negligible in phase III trials with many thousands of individuals enrolled in each trial arm, numerical experiments below indicate that the error may be non-negligible when there are under 1000 participants per trial, corresponding to small or intermediate size [18] or phase IIb challenge [19] trials. The bias may also be large when an appropriate subset of the data is used to estimate vaccine e ects for a speciÿc cohort. Jewell [20] provides a simple bias correction for relative risk and odds ratio estimators. His result applies directly to model II VE S estimators, because the model II VE S is the risk ratio subtracted from 1.
Standard estimators for model I VE S , VE I and VE R also have structural bias, because they are non-linear functions of estimators for risk in the placebo and vaccinated populations. However, the structural bias of those estimators has not yet been studied. This paper evaluates the structural bias of several vaccine e ect estimators. Some known bias corrections for model II susceptibility e ects are presented along with new bias corrections for model I VE S , VE I and VE R estimators. Both frequentist (Section 2) and Bayesian (Section 3) estimators are considered. Section 4 evaluates both the bias and root mean squared error (RMSE) of each estimator. Simulations indicate that bias corrections are appropriate when estimating risk ratios or vaccine e ects for a cohort with an appropriate subset of the data, for phase IIb, small or intermediate size trials, when the trial produces less data than expected from participants dropping out, or when the number of observed infections is less than anticipated during trial design.
FREQUENTIST VACCINE EFFECT ESTIMATORS
This section presumes that data from an appropriate vaccine trial design [4-6; 9 ] is available to estimate VE S , VE I and VE R . We ÿrst describe frequentist statistical issues for both model I and model II e ects for susceptibility (VE S ), then discuss VE I and VE R . Known bias corrections are reviewed and then new ones are proposed. Figure 1 . The magnitude of the ÿrst-order bias for model II VE S as a function of the number np = nv of individuals in each arm, the actual vaccine e ect (VE S = 0:3 and 0:6), and the probability of infection pp for a placebo recipient during the trial.
Model II susceptibility e ects
The model II vaccine e ect for susceptibility model presumes that a fraction of the vaccinated population is completely protected from all further exposure to infection, and that the remainder of the vaccinated population is una ected. Suppose that p p is the probability of infection over some deÿned time interval for a placebo recipient, and that p v is the corresponding probability for a vaccine recipient. The relative risk is = p v =p p , and the model II VE S is deÿned as
We recall three estimators for VE S . Let n p be the size of the uninfected placebo population, and let x p be the number that become infected during the trial. Let n v and x v be the corresponding quantities for the vaccinated population. Assuming conditionally independent Bernoulli trials, Haber et al. [2] estimates VE S aŝ
The MLEVE S is consistent, but biased because it is non-linear in the MLEp p for p p . A standard bias correctionb S; a:n: can be derived using a Taylor series expansion [17] VE S =VE S +b S; a:n: Figure 1 illustrates that the magnitude of this ÿrst-order bias changes as a function of the number n p = n v of individuals per arm, the actual vaccine e ect (VE S = 0:3 and 0:6), and the probability p p of infection for a placebo recipient during the trial. Doubling either n p or VE S halves the bias, and the bias worsens as p p approaches 0. Jewell [20] presents a bias correction for the relative risk that is computed as if an extra positive outcome were observed in the placebo population. That correction has an urn model interpretation [21] and determines a third model II VE S estimator
Both bias corrections increase the original estimate.
Model I susceptibility e ects
Model I vaccine e ects on susceptibility change the probability of infection per exposure. We recall an existing estimator for model I susceptibility e ects, and introduce two new bias corrections. Assume now that the outcome is infection and that infection status is only known at a speciÿed follow-up interval. Further assume that exposure events occur with rate for an individual in either the placebo or vaccinated population, and that p p is the probability of infection per exposure in the placebo population. Let p v be the corresponding probability for the vaccinated population. The model I VE S is deÿned to be
Over an elapsed time , the number of exposures has Poisson distribution with mean , so that the probability of infection during the trial is 
Haber et al. [2] derives this estimator with a di erential equation model. The ÿrst new bias correctionb S; lk for model I susceptibility e ects is obtained from the low-order terms of the Taylor series expansion (see the Appendix). This gives the model I e ect estimator analogous to the model II e ect estimator of equation (2) VE S =VE S +b S; lk
The second new bias correction for model I vaccine e ects for susceptibility is obtained by estimating the attack rate estimate in the placebo population by adding one to the positive count in the placebo population, as with the estimator in equation (3) 
Vaccine e ects on infectiousness
Vaccination may reduce the per-contact transmission probability from an infected individual. Several vaccine trial designs [4] [5] [6] measure vaccine e ects on infectiousness (VE I ) in terms of the probability of transmission per contact from infected placebo and vaccine recipients to uninfected, unvaccinated individuals. Let p be the transmission probability from an infected placebo recipient to an uninfected, unvaccinated individual, and let v be the corresponding probability from an infected vaccine recipient. Then
If the number of transmission opportunities during a given partnership between a vaccinated infected individual and an unvaccinated uninfected individual is unknown and assumed to be a Poisson random variable whose mean is the same in both trial arms, VE I can be estimated as with VE S in Section 2.2. Section 5 discusses potential violations of this assumption. Let m p be the number of partnerships between infected individuals in the placebo arm and uninfected, unvaccinated individuals, and let y p be the number of transmissions due to those partnerships. In a generic vaccine trial for sexually transmitted infections, m p would represent the sum of the number of partners reported by each individual in the placebo population. Let m v and y v be analogous quantities for the vaccine arm. ThenŜAR p = y p =m p andŜAR v = y v =m v are the MLEs for the partnership secondary attack rates in the placebo and vaccine arms. This secondary attack rate refers to a per partnership probability for secondary infection, rather than a per contact transmission probability. A simple modiÿcation of the standard model I VE S estimator leads to the following estimator for VE I e ects:
The ÿrst-order bias correction leads to the following new estimator for VE I :
A second new bias-corrected VE I estimator has a secondary attack rate estimator for the placebo population that is analogous to the model I VE S estimator in equation (6) 
Combined vaccine e ects
The combined e ect VE R of vaccination on the basic reproduction number R 0 depends on both VE S and VE I
In a homogeneously mixing population, R 0 is interpreted as the expected number of new infections caused by an infected individual in an otherwise entirely susceptible population, and VE R gives the relative reduction in R 0 when everybody is vaccinated. When R 0 ¿1, nonzero endemic infection levels are observed, and when R 0 ¡1 infections tend to die out. Longini et al. [4] indicate that the critical fraction f * of a homogeneously mixing population that must be vaccinated in order to eliminate endemic infection by reducing the basic reproduction number R 0 below 1 is f * = (R 0 − 1)=(R 0 VE R ). One estimator for VE R is determined by the MLEs for VE S and VE I [9; 22] 
Two new bias-corrected VE R estimators are obtained as above with the Taylor expansion (11) and with the modiÿed attack rate estimators for the placebo population
The biology of a particular vaccine might suggest that the model II VE S estimator is more appropriate for the estimation of VE R than the model I estimator considered here. The appropriate bias corrections for that vaccine would be derived similarly.
BAYESIAN ESTIMATORS
An alternative formulation that is consistent with existing Bayesian biostatistical literature [23] [24] [25] is to consider p p and p v to be independent random variables whose realizations are to be inferred from vaccine trial data and Bayes rule.
Bayesian vaccine e ects formulation
First consider model II susceptibility e ects. Although any joint prior distribution for p p and p v is valid, we use independent beta prior distributions for analytical tractability and consistency with Ashby et al. [25] Pr(p p ) ∼ beta( p ; ÿ p ) and
The prior probability density function of p p on the interval [0; 1] is therefore
The prior mean is p =( p + ÿ p ) (if p ; ÿ p ¿0) and prior mode is ( p − 1)=( p + ÿ p − 2) (if p ; ÿ p ¿1). Let E = (x p ; n p ; x v ; n v ; y p ; m p ; y v ; m v ) summarize the vaccine trial outcomes for the primary and secondary transmissions. The posterior distributions for p p is The posterior meanp p and variance˜ p 2 of the attack rate in the placebo population arẽ
Similar formulae hold for the posterior distribution of p v , and the quantitiesp v and˜ v 2 . For model I susceptibility e ects, we use a beta prior distribution for the unknown attack rates AR p ; AR v , rather than the per-contact transmission probabilities. Similarly, the partnership secondary attack rates SAR p ; SAR v are presumed to have beta prior distributions. The posterior means and variances of these unknown quantities are computed as in equation (15).
In what follows, we use ( p ; ÿ p ) = ( v ; ÿ v ) = (1=2; 1=2), a U-shaped, non-informative prior distribution, as did Ashby et al. [25] in a cancer risk study. Other choices are (1,1) for a uniform distribution, or to formally let ; ÿ → 0 to 'wash out' the in uence of the prior.
Posterior mean for vaccine e ects
The posterior expectation, conditional on the information E obtained from the trial, is an important Bayesian point estimator because it minimizes the squared error loss. The expected model II susceptibility e ect
is determined from the distributions in equation (14) , assuming that x p ¿ 0:5. The concept of bias correction is not applied in the standard Bayesian literature, so we do not consider a bias correction for
Similarly, the posterior expectation of the VE I and VE R are
where the posterior distributions for the partnership secondary attack rates p ; v are analogous to equation (14) . Monte Carlo sampling can be used to estimate
or to obtain credible sets (Bayesian conÿdence intervals).
Bayesian analogues of frequentist estimators
A second class of Bayesian point estimators are structurally similar to the frequentist estimators in Section 2, but substitute Bayesian concepts for frequentist ones. One Bayesian analoguẽ VE S of the frequentist model II e ect estimatorVE S uses posterior means instead of MLEs for the attack rate estimatesṼ
A Taylor series expansion forṼE S (see the Appendix) motivates the bias correctionb S; a:n:
VE S =ṼE S +b S; a:n:
A similar analysis applies for estimators of model I VE S and VE I , and of VE R
The Taylor series bias correction gives the estimator VE S =ṼE S +b S; lk Jewell [20] notes that the estimator 1 − V E S is not invariant to labelling changes (exchange placebo with vaccine arms). The estimator 1 −ṼE S is invariant to such changes.
EMPIRICAL EVALUATION OF VACCINE EFFECT ESTIMATORS
The bias and root mean squared error (RMSE) of all the above estimators are estimated empirically over a range of trial population sizes and known vaccine e ects. The goal is to identify the situations where the various estimators for each vaccine e ect perform particularly well or poorly in terms of bias and RMSE. The placebo and vaccine population sizes, n p ; n v , were set to 100, 300 and 1000 to evaluate the e ect of study population size on the bias and RMSE. These numbers correspond to small or intermediate size trials. While a reduction in susceptibility to infection of at least 60 per cent might be considered to be a substantial e ect, an intermediate size trial might be designed to screen out candidate vaccines with observed e cacies of 30 per cent or less [18] , and there may justiÿcation for studying low-e cacy vaccines [26] . The simulated susceptibility and infectiousness e ects are therefore set to 0.0, 0.3 and 0.6 to see how the bias changes with the magnitude of the e ect. The study focuses on the bias and RMSE of the vaccine estimates, and does not consider issues related to conÿdence intervals for standard estimators that have been treated elsewhere [27] . For each population size and vaccine e ect, estimates are generated from the sample statistics of 4000 independent trials. In each trial, the simulated vaccine e ect re ects the assumptions of the estimator (for example, model I e ects are simulated for model I estimators).
For the model II VE S simulations, the probability of infection in the placebo population is 0.07, and the probability of infection in the vaccinated population is 0:07 × (1 − VE S ). Table I presents bias estimates for all six all-or-one VE S estimators, and the RMSE is presented in Table II . The standard error ranges from 0:006 − 0:013 when n p = n v = 100, and is about 0:0013 − 0:0025 when n p = n v = 1000.
To aid in reading the tables, we recall that a hatˆdenotes an MLE, and a tilde˜indicates that Bayesian point estimates of the individual attack rates are used. Two symbols (ˆor˜) denote a ÿrst-order bias corrected estimator. The symbol ˆindicates that the attack rate for the placebo population is estimated by adding 1 to the number of positives. Finally, E[VE | E] represents the Bayesian posterior expectation of a vaccine e ect.
The conclusions drawn from the model II susceptibility estimators are equally applicable to relative risk estimators in general, since they are linear functions of each other. The estimators V E S andṼE S perform better than the other four estimators with respect to the magnitude of the bias. Their performance is within error for most situations, although V E S appears somewhat better for small populations (n p = n v = 100). The ÿrst-order bias corrections from the Taylor series expansion improves the bias of the estimators (VE S has less bias thanVE S , andṼE S has less bias thanṼE S ). The estimatorsVE S andVE S are undeÿned when the number of positive individuals in the placebo population is 0. The output of trials where that occurs is ignored, and results based sample averages where some trials are ignored are marked with * . The posterior expectation E[VE S | E] of the vaccine e ect has the worst bias of the six estimators considered here, and that the bias is signiÿcant even with n p = n v = 300 individuals per trial arm. In fact, it has twice the low-order bias ofṼE S because E[VE S | E] ≈ṼE S −b S; a:n: , whereasṼE S =ṼE S +b S; a:n: is a low-bias estimator.
We conjecture that the prior distribution in equation (13) for the unknown probabilities p p ; p v may be a culprit. In particular, one reason for implementing a vaccine trial is an a priori belief that p v ¡ p p , although there may be no e ect (p v = p p ) with a non-zero probability. Equation (13) implies, somewhat contradictorily, that the two unknown probabilities are statistically independent and there is 0 probability for no vaccine e ect. This suggests that using non-informative prior distributions for vaccine e ects speciÿcally, and for risk ratios in general, may lead to unintended and undesirable consequences. There appears to be a need for further work to help decision-makers specify prior distributions for vaccine e ect estimates that account for the beliefs about the likely biological e ects of vaccines. Table II illustrates that the RMSE of all of the model II VE S estimators (except E[VE S | E]) is roughly the same for larger population sizes, although the estimators with a Taylor series bias correction (VE S andṼE S ) seem to have a slight advantage over V E S , which is in turn somewhat better than the others. That the RMSE forVE S is particularly good when n p = n v = 100 is an artifact of the fact that trials with undeÿned estimators (division by 0) were not included in the computation.
The simulations that evaluate the model I VE S estimators assume that each trial participant experiences on average 10 exposures, with a Poisson distribution for the actual number of exposures. The per-contact transmission probability is set to ln(1 − 0:07)=10 ≈ 0:00726 in the placebo arm to obtain an attack rate of 0:07 in the placebo arm. The per-contact transmission rate in the vaccinated population is (1 − VE S ) ln(1 − 0:07)=10. The estimator with the smallest bias is again V E S , and the relative performance of the other estimators parallels that for the model II estimators, as shown in Table III. Table III . Bias estimates for model I VES estimators. The symbol * indicates that trials with undeÿned estimators (division by 0) were ignored in the computation.
Set-up
Frequentist Bayesian The RMSE for the model I VE S and VE I estimators (data not shown) are similar to those for the model II VE S estimators, in that estimators with a Taylor series bias correction have a slight advantage over V E S , which is in turn somewhat better than the others. The simulated trials for VE R e ects use the same assumptions used for the VE I simulations, except that both VE S and VE I are varied. Adjusting the bias of the attack rates by 'adding' a positive observation to the placebo population ( V E R ) again gives the best bias characteristics for the vaccine settings considered here, as supported by the bias estimates given in Table V. Unlike the other studies, however, the low-order Taylor series bias correction does not seem to appreciably improve the bias of the estimators. Table VI indicates that V E R exhibits the lowest RMSE. For a given VE R , the RMSE is slightly but consistently larger when VE S is larger. If n p = n v = 1000, for example, the RMSE of V E R is 0:170 when VE S = 0:6 and VE I = 0:3, but is 0:155 when VE S = 0:3 and VE I = 0:6.
The bias and RMSE of each estimator generally decrease as either or both of VE S and VE I change from 0.0 to 0.3 to 0.6. The notable exception is a moderately increased bias when VE S = VE I = 0:6, so that VE R = 0:84. When vaccine e ects are nearly one, the bias increases because fewer secondary infections are observed.
Additional simulations (results not shown) indicate that increasing the probability of becoming infected during the trial from 0.07-0.10 to 0.3 reduces the bias and RMSE, and reducing the probability of becoming infected during the trial to 0.05 increases the bias and RMSE, but the relative performance of the estimators does not appreciably change. When the simulation parameters are modiÿed so that 45 infections are expected in the control arm, as has been suggested for some intermediate-size trials [18] , the bias is somewhat improved with the Jewell-like estimators, but there is not a large improvement in the RMSE. These shifts are fully anticipated, as a somewhat increased probability of becoming infected during the trial leads to a smaller relative error in the attack rate estimators.
CONCLUSIONS
There are several vaccine e ects of interest in the control of infectious diseases, and many reasons why estimators of vaccine e ects may be biased. This study examines the bias that result from the non-linear structure of risk ratios.
Of six estimators for each of a variety of vaccine e ect estimators (several permutations of model I or model II e ects for susceptibility, infectiousness or combined e ects), including several new estimators, numerical results indicate that the estimator with the best bias and RMSE characteristics is computed by adding one to the count of positive outcomes in the placebo population. Although implementing this bias correction might seem to 'corrupt the data', doing so reduces both the bias and RMSE of standard vaccine e ect estimators.
The bias corrections above are most valuable when estimating risk ratios or vaccine e ects for a cohort with an appropriate subset of data, when the trial size is limited due to economic constraints, when the trial produces less data than expected from participants dropping out, or when the number of observed infections is somewhat less than anticipated during trial design. The structural bias is negligible, however, for large phase III trials.
Our analysis also highlights a systematic bias for a standard Bayesian treatment for risk ratios. The posterior expectation of vaccine e ects has twice the low-order bias of the MLE when independent non-informative prior distributions are used for the attack rates in the placebo and treatment populations. We conjecture that less bias might be achieved with prior distributions that better re ect the reasonable belief that a trial is being performed because a treatment has the potential of a beneÿcial e ect, although a potential for no e ect exists. Elicitation methods for appropriate prior distributions are an area for future work.
The assumption in Section 2.3 that the number of exposures is a Poisson random variable with common mean may not always be applicable. Partner tracing for sexually transmitted infections may provide more precise contact counts between each partner. In that case, partnership secondary attack rates can be estimated by conditioning on the number of reported contacts between infected participants and susceptible partners [28] , then using group test statistics [29] . If the number exposures per partner has a Poisson distribution with known means that vary in di erent population subgroups, limiting dilution assay statistics are appropriate [30; 31] . Standard vaccine e ect estimators are readily adapted to these situations by using the most appropriate secondary attack rate estimator. Still, reliable contact data may be di cult to obtain. Longini et al. [4] therefore provide alternative vaccine e cacy estimators based on data from multiple populations. Bias reductions for vaccine e ect estimators based on group tests, limiting dilution assays, and estimators of Longini et al. [4] are not proposed here.
In many trials it is important to assess vaccine e ects as a function of multiple covariates. The development and analysis of bias corrections for those vaccine e ect estimators is an area for future research.
APPENDIX that f = − 1=(1 − p v ), and f = − 1=(1 − p v ) 2 . The derivatives of g(p p ) are similar. This leads to the bias correction in equation (5) and equation (8) . The above analysis together with the derivative rule for products of functions lead to the bias correction in equation (11) .
Low-order correction for Bayesian point estimators
The low-order bias correction in the Bayesian model II susceptibility estimator in Section 3.3 is derived like the above classical estimators, except that one uses: (a) the Taylor series expansion for VE(p p ; p v ) around the posterior means (p p ;p v ), rather than the expansion for VE(p p ;p v ) around (p p ; p v ); (b) expectations with respect to the posterior distribution of (p p ; p v ), rather than with respect to the conditional distribution ofp p ;p v , given p p ; p v ; and (c) the posterior variance˜ p 2 for p p in equation (15) 
